i-Base home
Search Menu
  • Home
  • HTB
  • 2022
  • May

May 2022

Contents

Editorial

  • HTB May 2022 (2 May 2022)

Conference reports

  • 29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): third reports
  • CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART
  • CROI 2022: Other COVID-19 studies

Antiretrovirals

  • FDA approves dispersible dolutegravir/abacavir/3TC for children
  • Access to ibalizumab uncertain in Europe: TaiMed looking for new partner after Thera quits

Coinfections and complications

  • Asymptomatic COVID-19 is common in people living with HIV
  • Longest COVID-19 infection lasted 505 days in an immunocompromised person in London
  • Herd immunity unlikely to control COVID-19: opinion article from US NIAID
  • The challenges of prioritising access to molnupiravir and nirmatrelvir–ritonavir for COVID-19
  • Increased risk of blood clots after COVID-19: higher with underlying conditions and more severe symptoms
  • Two new platform vaccines against COVID-19 report phase 3 results

HIV prevention and transmission

  • A&E adopts opt-out HIV testing in London, Manchester, Salford and Brighton
  • Zimbabwe decriminalises HIV transmission

Cure-related research

  • Community webinar series on HIV cure-related cell and gene therapy

Other news

  • Family of Greek activist Zak Kostopoulos decry minimal sentence given to his killers

PDFs

  • HTB: no. 5 (2 May 2022) PDF downloads
  • HTB RSS

Early access

  • Vaccination is effective in limiting mpox progression – but lower efficacy in people living with HIV 27 May 2025
  • US update guidelines for statin use in people living with HIV 26 May 2025
  • HIV activists in the US call for action in JID and Zachie Achmet brings South African perspective in the Lancet 26 May 2025
  • Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement 22 May 2025
  • All early access reports

Current issues

  • May 2025
  • April 2025
  • March 2025
  • Back issues

Special report

  • Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement 22 May 2025

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage
  • Donate

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
Registered charity number: 1081905. Company number: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Donate
Feedback
Advice and information
Q and A
Guides
HIV meds
Glossary
Research reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
News and updates
Sitemap
Home
Find us on Facebook
i-Base on Facebook